{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:20:25Z","timestamp":1793488825344,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jid.2020.07.038","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T19:19:23Z","timestamp":1602357563000},"page":"830-839.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010\u20132017"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-361X","authenticated-orcid":false,"given":"Florence","family":"Poizeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4119-203X","authenticated-orcid":false,"given":"Sandrine","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9487-1533","authenticated-orcid":false,"given":"Andr\u00e9","family":"Happe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-0653","authenticated-orcid":false,"given":"Caroline","family":"Rault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4054-5668","authenticated-orcid":false,"given":"Erwan","family":"Drezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-1361","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Balusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5698-9215","authenticated-orcid":false,"given":"Philippe","family":"Tuppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-4136","authenticated-orcid":false,"given":"Bernard","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-3084","authenticated-orcid":false,"given":"Anne","family":"Thuret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-0139","authenticated-orcid":false,"given":"Lise","family":"Boussemart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-4340","authenticated-orcid":false,"given":"Monica","family":"Dinulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8110-0780","authenticated-orcid":false,"given":"Marc","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-5135","authenticated-orcid":false,"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-6643","authenticated-orcid":false,"given":"Catherine","family":"Droitcourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9837-2977","authenticated-orcid":false,"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3212-7455","authenticated-orcid":false,"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.07.038_bib1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.jid.2020.07.038_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2020.07.038_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1684\/ejd.2019.3558","article-title":"Efficacy and safety of nivolumab in metastatic melanoma: real-world practice","volume":"29","author":"Bocquet-Tremoureux","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2020.07.038_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib6","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.28306","article-title":"Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma","volume":"119","author":"Bucheit","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jid.2020.07.038_bib8","doi-asserted-by":"crossref","first-page":"e16328","DOI":"10.1097\/MD.0000000000016328","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: a retrospective, community oncology-based cohort study (a STROBE-compliant article)","volume":"98","author":"Cowey","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jid.2020.07.038_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jama.297.3.314","article-title":"Estimating treatment effects using observational data","volume":"297","author":"D\u2019Agostino","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2020.07.038_bib10","author":"Defossez"},{"key":"10.1016\/j.jid.2020.07.038_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2018.12.002","article-title":"The real-world impact of modern treatments on the survival of patients with metastatic melanoma","volume":"108","author":"Donia","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib14","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","article-title":"New drugs in melanoma: it\u2019s a whole new world","volume":"47","author":"Eggermont","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib15","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib16","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00432-016-2309-y","article-title":"Improvement of overall survival in stage IV melanoma patients during 2011\u20132014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR)","volume":"143","author":"Forschner","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2010.10.001","article-title":"Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group","volume":"47","author":"Fraser","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600\u2013mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/CAD.0000000000000629","article-title":"Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in the Netherlands","volume":"29","author":"Jochems","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jid.2020.07.038_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.09.026","article-title":"Update of survival and cost of metastatic melanoma with new drugs: estimations from the MelBase cohort","volume":"105","author":"Kandel","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib24","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib27","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib28","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2217\/fon-2018-0964","article-title":"Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study","volume":"15","author":"Luke","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/CMR.0000000000000359","article-title":"Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland","volume":"27","author":"Mangana","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2020.07.038_bib30","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1002\/cam4.2625","article-title":"Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab","volume":"8","author":"Moser","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2020.07.038_bib31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","article-title":"Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma","volume":"59","author":"Moser","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib32","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00432-017-2453-z","article-title":"Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data","volume":"143","author":"Polkowska","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2013.53.0204","article-title":"Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients","volume":"32","author":"Prasad","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.07.038_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2015-0478","article-title":"Sorafenib effectiveness in advanced hepatocellular carcinoma","volume":"21","author":"Sanoff","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jid.2020.07.038_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-019-02311-1","article-title":"First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis","volume":"68","author":"Schilling","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2020.07.038_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/CMR.0000000000000453","article-title":"Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes","volume":"28","author":"Schouwenburg","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2020.07.038_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jama.297.3.278","article-title":"Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods","volume":"297","author":"Stukel","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2020.07.038_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/cer-2019-0003","article-title":"Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA","volume":"8","author":"Tarhini","year":"2019","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.jid.2020.07.038_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.02.009","article-title":"Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort","volume":"112","author":"T\u00e9tu","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.jid.2020.07.038_bib42","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.jid.2020.07.038_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.07.038_bib44","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.07.038_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2217\/fon-2018-0620","article-title":"Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices","volume":"15","author":"Whitman","year":"2019","journal-title":"Future Oncol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20321382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20321382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:21:54Z","timestamp":1758302514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20321382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0022202X20321382"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.07.038","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010\u20132017","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}